Cellectar (NASDAQ: CLRB) COO boosts stake with common stock and warrant buys

Filing Impact

(Neutral)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Cellectar Biosciences, Inc. Chief Operating Officer Jarrod Longcor reported open-market purchases of common stock and warrants. On 2026-05-07, he bought 8,680 shares of common stock at $2.88 per share. He also bought 26,040 warrants at $0.01 per warrant, each exercisable for one share of common stock at an exercise price of $2.88.

After these transactions, his direct holdings increased to 20,451 common shares and 36,149 warrants. A footnote explains the warrants are split into Tranche A, Tranche B, and Tranche C, with terms of one, two, and five years, respectively, from the date of stockholder approval.

Insider Trade Summary

Net Buyer: 34,720 shares ($25,259)

Net Buy 2 txns

Insider Longcor Jarrod

Role Chief Operating Officer

Bought 34,720 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Warrants	26,040	$0.01	$260.40
Purchase	Common Stock	8,680	$2.88	$25K

Holdings After Transaction: Warrants — 36,149 shares (Direct, null); Common Stock — 20,451 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Common shares purchased: 8,680 shares Purchase price per common share: $2.88/share Warrants purchased: 26,040 warrants +4 more

7 metrics

Common shares purchased 8,680 shares Open-market purchase on May 7, 2026 at $2.88

Purchase price per common share $2.88/share Open-market common stock transaction on May 7, 2026

Warrants purchased 26,040 warrants Open-market derivative purchase on May 7, 2026 at $0.01

Warrant purchase price $0.01/warrant Derivative transaction on May 7, 2026

Warrant exercise price $2.88/share Exercise price for underlying common stock

Common shares held after 20,451 shares Direct common stock holdings following transactions

Warrants held after 36,149 warrants Direct warrant holdings following transactions

Key Terms

open-market purchase, Warrants, exercise price, Tranche A, +2 more

6 terms

open-market purchase financial

"reporting open-market purchases of common stock and warrants"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Warrants financial

"He also bought 26,040 warrants at $0.01 per warrant"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

exercise price financial

"each exercisable for one share of common stock at an exercise price of $2.88"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Tranche A financial

"warrants are split into Tranche A, Tranche B, and Tranche C"

Tranche B financial

"Tranche B shall have a two-year term from the date of stockholder approval"

Tranche C financial

"Tranche C shall have a five-year term from the date of stockholder approval"

Form 4 Insider Transactions: What Each Field Means →

05/11/2026 - 08:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Longcor Jarrod

(Last)

(First)

(Middle)

C/O CELLECTAR BIOSCIENCES, INC.

100 CAMPUS DRIVE

(Street)

FLORHAM PARK

NEW JERSEY

07932

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cellectar Biosciences, Inc. [ CLRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/07/2026		P		8,680	A	$2.88	20,451	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrants	$2.88	05/07/2026		P		26,040		05/07/2026	⁽¹⁾	Common Stock	26,040	$0.01	36,149	D

Explanation of Responses:

1. Expiration dates are as follows: Tranche A shall have a one-year term from the date of stockholder approval; Tranche B shall have a two-year term from the date of stockholder approval; Tranche C shall have a five-year term from the date of stockholder approval.

	/s/ Christina Blakley, attorney-in-fact for Jarrod D. Longcor	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Cellectar Biosciences (CLRB) report for Jarrod Longcor?

Cellectar Biosciences reported that COO Jarrod Longcor made open-market purchases of common stock and warrants. He bought 8,680 common shares and 26,040 warrants on May 7, 2026, increasing both his share and warrant holdings.

How many Cellectar (CLRB) common shares did the COO buy and at what price?

COO Jarrod Longcor bought 8,680 Cellectar common shares at a price of $2.88 per share. These were open-market purchases and raised his direct common stock holdings to 20,451 shares following the transaction.

What warrants did Cellectar Biosciences (CLRB) COO purchase and on what terms?

Jarrod Longcor purchased 26,040 Cellectar warrants at $0.01 per warrant, each exercisable for one common share at $2.88. A footnote states Tranche A, B, and C have one-, two-, and five-year terms from stockholder approval.

What are Jarrod Longcor’s holdings in Cellectar (CLRB) after the reported Form 4?

Following the May 7, 2026 transactions, Jarrod Longcor directly holds 20,451 Cellectar common shares and 36,149 warrants. The warrant position reflects aggregation after the new purchase of 26,040 warrants disclosed in this Form 4 filing.

Were the Cellectar (CLRB) insider transactions open-market purchases or another type?

Both transactions reported by COO Jarrod Longcor were open-market purchases. The Form 4 identifies them with code P, described as purchases in open-market or private transactions, covering common stock and derivative warrants.